These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1341447)

  • 41. Increase of resting levels of superoxide anion in the whole blood of patients with decompensated liver cirrhosis.
    Chen MF; Mo LR; Lin RC; Kuo JY; Chang KK; Liao C; Lu FJ
    Free Radic Biol Med; 1997; 23(4):672-9. PubMed ID: 9215813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients.
    Collazos J; Genollà J; Ruibal A
    Int J Biol Markers; 1992; 7(4):244-8. PubMed ID: 1491181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum concentrations of laminin in cirrhosis of the liver.
    Collazos J; Díaz F; Genollá J
    Gut; 1993 Jul; 34(7):974-6. PubMed ID: 8344586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and Implications of Abnormal Laboratory Results in Patients in the Terminal Phase of Life.
    Masman AD; Tibboel D; Baar FP; van Dijk M; Mathot RA; van Gelder T
    J Palliat Med; 2016 Aug; 19(8):822-9. PubMed ID: 27494223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for ovarian cancer. Other chronic diseases affect serum marker.
    Tambyah P; Yap I; Lye WC
    BMJ; 1993 Jun; 306(6893):1684; author reply 1685-6. PubMed ID: 8369066
    [No Abstract]   [Full Text] [Related]  

  • 46. Serum CA 125 levels in patients with non-malignant liver diseases without ascites.
    Collazos J; Genolla J; Allende MT; Ruibal A
    Clin Investig; 1993 Mar; 71(3):239. PubMed ID: 8481627
    [No Abstract]   [Full Text] [Related]  

  • 47. Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis.
    Bertino G; Ardiri AM; Boemi P; Bruno CM; Valenti M; Mazzarino MC; Consolo M; Calvagno GS; Pulvirenti D; Neri S
    Minerva Gastroenterol Dietol; 2007 Dec; 53(4):305-9. PubMed ID: 18043548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.
    Schöniger-Hekele M; Müller C
    Dig Dis Sci; 2006 Feb; 51(2):338-45. PubMed ID: 16534678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis.
    Deugnier YM; Rabot AF; Guyader D; Moirand R; Turlin B; Boucher E; Lebert P; Brissot P
    Gut; 1994 Aug; 35(8):1107-11. PubMed ID: 7926915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepatic disorders.
    Collazos J; Genollá J; Ruibal A
    Scand J Clin Lab Invest; 1993 Oct; 53(6):633-7. PubMed ID: 8266011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis.
    Haukeland JW; Schreiner LT; Lorgen I; Frigstad SO; Bang C; Raknerud N; Konopski Z
    Scand J Gastroenterol; 2008; 43(10):1241-8. PubMed ID: 18609128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC.
    Nyblom H; Björnsson E; Simrén M; Aldenborg F; Almer S; Olsson R
    Liver Int; 2006 Sep; 26(7):840-5. PubMed ID: 16911467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and laboratory evaluation of CA 19-9 in cirrhotic patients.
    Collazos J
    Eur J Med; 1992; 1(4):215-8. PubMed ID: 1341447
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.